The US Food and Drug Administration (FDA) has extended the time needed to review clinical-stage biotechnology company Humacyte’s biologic license application (BLA) for its implant, the Acellular ...
Humacyte (HUMA) announced the presentation of positive results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel, ATEV, in arteriovenous, AV, access for patients with ...
(RTTNews) - Shares of Humacyte, Inc. (HUMA) fell more than 10% in after-hours trading Friday after the Food and Drug Administration said it will require more time to review acellular tissue engineered ...
DURHAM, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
DURHAM, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Humacyte (NASDAQ:HUMA) stock fell 18% in after-hours trading Friday after the company said the FDA has informed the company that it will need additional time to complete its review of the Biologics ...
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – ...
– In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results